申请人:Glinka Tomasz
公开号:US20080076741A1
公开(公告)日:2008-03-27
Disclosed herein are Efflux Pump Inhibitor (EPI) compounds that can be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. It is demonstrated that the EPIs can be used to increase the potency, decrease bacterial resistance and development of bacterial resistance, and increase killing effectivness of tigecycline. Also disclosed are methods of treatment and pharmaceutical compositions for co-administering tigecylcine with an EPI.
本文公开了外排泵抑制剂(EPI)化合物,可以与抗微生物药物联合使用,用于治疗由耐药病原体引起的感染。这些EPI化合物是软药物,具有降低组织积累的倾向。证明EPI可以用于增加替加环素的效力,降低细菌耐药性和细菌耐药性的发展,并增加杀菌效果。同时,还公开了联合使用替加环素和EPI的治疗方法和制药组合物。